5 completed, 2 unknown, 1 terminated, 1 withdrawn. 4 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 3 | Unknown 2, Terminated 1 |
Follow GV1001 peptide: new trials by email Literature Review of GV1001 peptide trials Research Report on GV1001 peptide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects GV1001, Placebo - Neuro-Degenerative Disease | Phase 1 | Completed | GemVax & Kael | 59 | 2024-10-08 | 2025-11-19 |
| GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD) GV1001, Normal saline - Moderate Alzheimer's Disease | Phase 2 | Withdrawn | GemVax & Kael | 2019-09-01 | 2022-03-03 | |
| A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients GV1001, Gemcitabine, Capecitabine - Pancreatic Cancer | Phase 3 | Unknown | Samsung Pharmaceutical Co., Ltd. | 148 | 2015-11-01 | 2016-11-22 |
| A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH Placebo, GV1001 - Benign Prostatic Hyperplasia (BPH) | Phase 2 | Completed | GemVax & Kael | 161 | 2015-10-01 | 2022-03-04 |
| Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer GV1001, normal saline - Inoperable Stage III Non-small Cell Lung Cancer | Phase 3 | Unknown | Kael-GemVax Co., Ltd. | 600 | 2012-05-01 | 2012-04-19 |
| A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma LTX-315 - Carcinoma | Phase 1 | Completed | Lytix Biopharma AS | 12 | 2010-08-01 | 2012-01-11 |
| A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma. GV1001 - Carcinoma, Hepatocellular | Phase 2 | Completed | Pharmexa A/S | 41 | 2006-11-01 | 2008-12-18 |
| GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer GV1001, Gemcitabine (Chemotherapy) - Advanced Unresectable Pancreatic Cancer | Phase 3 | Terminated | Pharmexa A/S | 360 | 2006-06-01 | 2008-05-19 |
| Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma GV1001 - Malignant Melanoma | Phase 1 / Phase 2 | Completed | Oslo University Hospital | 2005-01-01 | 2014-11-05 |
Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Alzheimer Disease (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Melanoma (1) · Neoplasms (1) · Prostatic Hyperplasia (1)
GemVax & Kael (3) · Pharmexa A/S (2) · Kael-GemVax Co., Ltd. (1) · Lytix Biopharma AS (1) · Oslo University Hospital (1) · Samsung Pharmaceutical Co., Ltd. (1)
Norway (3) · South Korea (3) · France (2) · Spain (2) · Australia (1) · Belgium (1) · Denmark (1) · Germany (1) · Ireland (1) · Italy (1) · Netherlands (1) · Poland (1) · Sweden (1) · United States (1)
Ask Aabenhus, MSc. (Pharm) (1) · Chang-Hwan Park, M.D. (1) · Eun Kwang Choi, M.D. (1) · Gwang Ha Kim, M.D. (1) · Ho Gak Kim, M.D. (1) · Ho Soon Choi, M.D. (1) · Hong Sik Lee, M.D. (1) · Jae Hee Cho, M.D. (1) · Jae Yong Cho, M.D. (1) · Joung-Ho Han, M.D. (1) · Kwang Hyuck Lee, M.D. (1) · Kyong Joo Lee, M.D. (1) · Kyung Seop Lee (1) · Kyung-Sang Yu, M.D., Ph.D. (1) · Lotte Rosendahl, Pharmacist (CTM) (1)